Skip to main content
GutCited
Figure 3. Change in stool consistency from baseline (visit 2/d 1) to end of treatment (visit 4/d 80) in Test-G and Placebo-H. The Bristol stool form scale is used to assess the stool consistency as reported by total number of subjects.
Figure 4. Figure 3. Change in stool consistency from baseline (visit 2/d 1) to end of treatment (visit 4/d 80) in Test-G and Placebo-H. The Bristol stool form scale is used to assess the stool consistency as reported by total number of subjects.

Descripción

Stool consistency changes from baseline to end of treatment are assessed using the Bristol Stool Form Scale. The Bacillus coagulans group shows normalization toward type 3-4 stools compared to placebo.

More Figures from This Paper

Total IBS symptom scores decrease significantly in the Bacillus coagulans LBSC group compared to placebo over the treatment period. Both bloating and abdominal pain subscores show improvement.

Figure 2

Total IBS symptom scores decrease significantly in the Bacillus coagulans LBSC group compared to placebo over the treatment period. Both bloating and abdominal pain subscores show improvement.

chart
Individual IBS symptom domains including bloating, abdominal pain, urgency, and incomplete evacuation are tracked across study visits. Bacillus coagulans supplementation shows benefits across multiple symptom dimensions.

Figure 3

Individual IBS symptom domains including bloating, abdominal pain, urgency, and incomplete evacuation are tracked across study visits. Bacillus coagulans supplementation shows benefits across multiple symptom dimensions.

chart
Principal component analysis of quality of life responses clusters patients by treatment arm. Bacillus coagulans-treated patients show greater separation from baseline values, indicating improved quality of life dimensions.

Figure 5

Principal component analysis of quality of life responses clusters patients by treatment arm. Bacillus coagulans-treated patients show greater separation from baseline values, indicating improved quality of life dimensions.

chart

Figure 4

Chart
721 × 568px · 82,1 KB

Source Paper

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT …

Medicine (2021)

PMID: 33545934

DOI: 10.1097/MD.0000000000023641

Cite This Figure

![Figure 4: Stool consistency changes from baseline to end of treatment are assessed using the Bristol Stool Form Scale. The Bacillus coagulans group shows normalization toward type 3-4 stools compared to placebo.](https://pdfs.citedhealth.com/figures/33545934/149.png)

> Source: Anil Kumar Gupta et al. "Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A pr." *Medicine*, 2021. PMID: [33545934](https://pubmed.ncbi.nlm.nih.gov/33545934/)
<figure>
  <img src="https://pdfs.citedhealth.com/figures/33545934/149.png" alt="Stool consistency changes from baseline to end of treatment are assessed using the Bristol Stool Form Scale. The Bacillus coagulans group shows normalization toward type 3-4 stools compared to placebo." />
  <figcaption>Figure 4. Stool consistency changes from baseline to end of treatment are assessed using the Bristol Stool Form Scale. The Bacillus coagulans group shows normalization toward type 3-4 stools compared to placebo.<br>  Source: Anil Kumar Gupta et al. "Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A pr." <em>Medicine</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33545934/">33545934</a></figcaption>
</figure>

Evidencia relacionada

B
Bacillus coagulans para Irritable Bowel Syndrome (IBS)

Calificación B · 3 estudios